S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Sell every Stock except ONE (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Sell every Stock except ONE (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Sell every Stock except ONE (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Sell every Stock except ONE (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NASDAQ:ISPC

iSpecimen (ISPC) Stock Forecast, Price & News

$1.25
-0.01 (-0.79%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$1.22
$1.30
50-Day Range
$1.23
$1.88
52-Week Range
$1.17
$3.26
Volume
39,000 shs
Average Volume
26,040 shs
Market Capitalization
$11.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.63

iSpecimen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
510.0% Upside
$7.63 Price Target
Short Interest
Healthy
0.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of iSpecimen in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

171st out of 1,010 stocks

Commercial Physical Research Industry

7th out of 16 stocks


ISPC stock logo

About iSpecimen (NASDAQ:ISPC) Stock

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Receive ISPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iSpecimen and its competitors with MarketBeat's FREE daily newsletter.

ISPC Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
iSpecimen Reports First Quarter 2023 Results
Contrasting iSpecimen (ISPC) and Its Rivals
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
iSpecimen (ISPC) and Its Rivals Head-To-Head Analysis
Contrasting iSpecimen (ISPC) & Its Peers
Reviewing iSpecimen (ISPC) and The Competition
Financial Analysis: iSpecimen (ISPC) versus Its Peers
iSpecimen (ISPC) vs. Its Competitors Head-To-Head Comparison
iSpecimen (ISPC) and Its Competitors Financial Survey
iSpecimen (ISPC) vs. Its Competitors Financial Contrast
Critical Review: iSpecimen (ISPC) and Its Peers
Head-To-Head Review: iSpecimen (ISPC) and Its Competitors
iSpecimen (ISPC) versus Its Rivals Head to Head Survey
Financial Survey: iSpecimen (ISPC) and Its Peers
Head-To-Head Survey: iSpecimen (ISPC) & The Competition
iSpecimen (ISPC) & Its Competitors Critical Comparison
Contrasting iSpecimen (ISPC) & The Competition
iSpecimen (ISPC) & Its Rivals Head to Head Contrast
Financial Review: iSpecimen (ISPC) vs. Its Peers
Analyzing iSpecimen (ISPC) and Its Peers
See More Headlines
Receive ISPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iSpecimen and its competitors with MarketBeat's FREE daily newsletter.

ISPC Company Calendar

Last Earnings
3/14/2023
Today
5/28/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISPC
Fax
N/A
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.63
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$4.25
Forecasted Upside/Downside
+510.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,250,000.00
Pretax Margin
-95.02%

Debt

Sales & Book Value

Annual Sales
$10.40 million
Book Value
$2.00 per share

Miscellaneous

Free Float
6,077,000
Market Cap
$11.29 million
Optionable
Not Optionable
Beta
1.94

Key Executives

  • Ms. Tracy Wilson Curley (Age 60)
    CFO, Treasurer & Interim CEO
    Comp: $367k
  • Dr. Christopher J. Ianelli M.D. (Age 54)
    Ph.D., Founder & Director
    Comp: $440k
  • Mr. Benjamin Bielak (Age 52)
    Chief Information Officer
    Comp: $334k
  • Ms. Jill Mullan (Age 57)
    Sec. & Director
    Comp: $391.25k
  • Ms. Dawn Michelle
    VP of Operations
  • Mr. Eric Langlois
    Sr. VP of Sales & Bus. Devel.
  • Ms. Carly Lejnieks
    VP of Marketing
  • Ms. Emily Hubbard
    VP of Site Management & Devel.
  • Mr. David Wages M.D.
    Ph.D., Chief Medical Officer













ISPC Stock - Frequently Asked Questions

Should I buy or sell iSpecimen stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iSpecimen in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ISPC shares.
View ISPC analyst ratings
or view top-rated stocks.

What is iSpecimen's stock price forecast for 2023?

1 equities research analysts have issued twelve-month price objectives for iSpecimen's stock. Their ISPC share price forecasts range from $4.25 to $11.00. On average, they predict the company's share price to reach $7.63 in the next year. This suggests a possible upside of 510.0% from the stock's current price.
View analysts price targets for ISPC
or view top-rated stocks among Wall Street analysts.

How have ISPC shares performed in 2023?

iSpecimen's stock was trading at $1.3750 on January 1st, 2023. Since then, ISPC shares have decreased by 9.1% and is now trading at $1.25.
View the best growth stocks for 2023 here
.

Are investors shorting iSpecimen?

iSpecimen saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 28,100 shares, a decline of 43.0% from the April 30th total of 49,300 shares. Based on an average daily volume of 30,900 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.5% of the shares of the company are short sold.
View iSpecimen's Short Interest
.

When is iSpecimen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ISPC earnings forecast
.

How were iSpecimen's earnings last quarter?

iSpecimen Inc. (NASDAQ:ISPC) released its quarterly earnings results on Tuesday, March, 14th. The company reported ($0.24) earnings per share for the quarter. The business earned $2.96 million during the quarter. iSpecimen had a negative net margin of 95.03% and a negative trailing twelve-month return on equity of 47.82%.

When did iSpecimen IPO?

(ISPC) raised $20 million in an initial public offering on Thursday, June 17th 2021. The company issued 2,200,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is iSpecimen's stock symbol?

iSpecimen trades on the NASDAQ under the ticker symbol "ISPC."

How do I buy shares of iSpecimen?

Shares of ISPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iSpecimen's stock price today?

One share of ISPC stock can currently be purchased for approximately $1.25.

How much money does iSpecimen make?

iSpecimen (NASDAQ:ISPC) has a market capitalization of $11.29 million and generates $10.40 million in revenue each year. The company earns $-10,250,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How can I contact iSpecimen?

The official website for the company is ispecimen.com. The company can be reached via phone at 781-301-6700 or via email at ispecimen@kcsa.com.

This page (NASDAQ:ISPC) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -